Latest
-
GlaxoSmithKline set to submit Relovair to regulators
News Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-daily respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
News -
Earnings at the lower end of forecasts, says AstraZeneca
News Biopharmaceutical giant AstraZeneca has said that full-year earnings are now expected to come in at the lower end of previous guidance.
News -
SkyePharma rocked by regulatory delay
News Drugs developer SkyePharma was sailing close to its 52-week low after it announced another regulatory delay for its asthma treatment, Flutiform.
News -
AstraZeneca and Hutchison seal cancer drug deal
News FTSE 100 pharmaceuticals firm AstraZeneca and Hutchison MediPharma (HMP), a research and development company majority-owned by Chi-Med, have entered into a global licensing, co-development, and commercialisation agreement for a cancer treatment drug.
News -
Glaxo offloads non-core assets in US and Canada
News Pharmaceuticals giant GlaxoSmithKline, which announced back in February its intention to get rid of its Consumer Healthcare OTC brands, has now reached an agreement with Prestige Brands Holdings to sell these non-core US and Canadian brands for £426m cash.
News -
Failed drug tests hit AstraZeneca earnings
News Pharmaceutical giant AstraZeneca has warned earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests.
News -
Fusion IP signs agreement with pharmaceutical company
News Fusion IP, which commercialises university research, has signed an agreement with a pharmaceutical company utilising intellectual property out of the University of Sheffield, for the development of a known drug.
News -
AstraZeneca lays off 1,150 in US, takes one-off charge
News Pharmaceuticals giant AstraZeneca is to cut 1,150 jobs from its sales force in the US, as part of its "ongoing strategy to operate its business more efficiently to best serve patients".
News -
Yule Catto sells pharma division to Vivimed
News Yule Catto, the Essex headquartered polymer business, has sold its pharmaceuticals division, Uquifa, to the Indian firm Vivimed Labs.
News